Cargando…
Neutralizing monoclonal antibodies against SARS-CoV-2 for COVID-19 pneumonia in a rituximab treated patient with systemic sclerosis—A case report and literature review
Patients with immune-mediated diseases (IMID) such as systemic sclerosis (SSc), who are treated with B cell depleting treatments, are at risk for developing severe COVID-19 due to inadequate humoral immune response. During B cell depletion, therapeutic substitution of neutralizing monoclonal antibod...
Autores principales: | Yalcin Mutlu, Melek, Taubmann, Jule, Wacker, Jochen, Tascilar, Koray, Fagni, Filippo, Gerner, Maximilian, Klett, Daniel, Schett, Georg, Manger, Bernhard, Simon, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381861/ https://www.ncbi.nlm.nih.gov/pubmed/35991632 http://dx.doi.org/10.3389/fmed.2022.934169 |
Ejemplares similares
-
Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination
por: Fagni, Filippo, et al.
Publicado: (2022) -
Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study
por: Simon, David, et al.
Publicado: (2022) -
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses
por: Fagni, Filippo, et al.
Publicado: (2021) -
Tolerability of low to moderate biomechanical stress during leisure sport activity in patients with psoriasis and psoriatic arthritis
por: Fagni, Filippo, et al.
Publicado: (2023) -
Humoral and Cellular Immune Responses to SARS–CoV‐2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion
por: Simon, David, et al.
Publicado: (2021)